COYA
Coya Therapeutics, Inc.
Biotechnology · Healthcare · United States
3.61
close · 2026-10-30
value
34
cheaper than peers34
quality
27
stronger fundamentals27
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.96× | 69 |
| price to sales | 10.56× | 51 |
| cash flow yield, 3 years ago | -8.5% | 46 |
| cash flow yield, latest year | -12.7% | 46 |
| cash flow yield, 1 year ago | -12.1% | 44 |
| earnings yield, 2 years ago | -21.9% | 44 |
| cash flow yield, 2 years ago | -13.2% | 41 |
| earnings yield, 1 year ago | -27.1% | 41 |
| earnings yield, latest year | -35.2% | 30 |
| earnings yield, 3 years ago | -131.0% | 12 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 49.0% | 66 |
| return on equity | -60.5% | 42 |
| operating margin | -2890.5% | 9 |
3 of 4 measures available
Facts
| market cap | $85M |
| free cash flow | -$12.0M |
| employees | 8 |
| first trade | 2022-12-29 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.27 | -0.98 | -0.79 | -4.73 | not reported |
| free cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.2M | not reported |
| net income | -$21.2M | -$14.9M | -$8.0M | -$12.2M | not reported |
| revenue | $7.9M | $3.6M | $6.0M | $0 | not reported |
| unusual items | not reported | not reported | -$543,186 | -$2.5M | $0 |